BiotechTube

Bexarotene

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thyroid Cancer

Conditions

Thyroid Cancer

Trial Timeline

Nov 1, 2008 → Feb 1, 2013

NCT ID
NCT00718770

About Bexarotene

Bexarotene is a phase 1 stage product being developed by Eisai for Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00718770. Target conditions include Thyroid Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT00050973Phase 3Completed
NCT00718770Phase 1Completed

Competing Products

20 competing products in Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
MBX 2109MBX BiosciencesPhase 2
47
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionMBX BiosciencesPhase 2
47
PCO371 + PlaceboChugai PharmaceuticalPhase 1
33
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
41
efatutazone + paclitaxelDaiichi SankyoPhase 2
52
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
52
LenvatinibEisaiPre-clinical
23
LenvatinibEisaiPre-clinical
23
Lenvatinib + Placebo + LenvatinibEisaiPhase 3
77
Irofulven + capecitabineEisaiPhase 2
52
Lenvatinib + PlaceboEisaiPhase 3
77
LenvatinibEisaiApproved
85
LenvatinibEisaiPre-clinical
23
Lenvatinib + Lenvatinib matching placeboEisaiPhase 2
52
LenvatinibEisaiPhase 2
52
LENVATINIBEisaiPhase 2
52
E7080 capsuleEisaiPhase 2
52
Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort)EisaiPhase 2
52
Lenvatinib 24 mgEisaiPhase 2
52
KHK7580 + KRN1493Kyowa KirinPhase 2/3
65

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85